Tech Center 1600 • Art Units: 1641 1653 1699
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18557836 | METHOD FOR PRODUCING CELLS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18375035 | A METHOD OF PRODUCING A CARDIOMYOCYTE SPHEROID | Non-Final OA | KANEKA CORPORATION |
| 17960655 | PRODUCTS AND METHODS TO ISOLATE MITOCHONDRIA | Final Rejection | Beth Israel Deaconess Medical Center, Inc. |
| 17434912 | A NUTRITIONAL COMPOSITION FOR USE TO ENHANCE EXECUTIVE FUNCTION | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18034278 | FIXATIVE COMPOSITIONS AND METHODS OF PRESERVING BIOLOGICAL SAMPLES | Non-Final OA | UNIVERSITY HEALTH NETWORK |
| 17915086 | METHODS, COMPOSITIONS, AND SYSTEMS FOR ENHANCING EX-VIVO ORGAN PERFUSION | Non-Final OA | University Health Network |
| 17908810 | METHODS AND SYSTEMS TO PRINT AND MATURE TISSUES OVER TIME IN A THREE-DIMENSIONAL SUPPORT MATRIX | Non-Final OA | The General Hospital Corporation |
| 18267230 | METHOD FOR MASS PRODUCTION OF HIGHLY PURE, STEM CELL-DERIVED EXTRACELLULAR VESICLE BY USING PEPTIDE | Non-Final OA | KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP |
| 18342676 | METHODS OF GENERATING MYCELIAL SCAFFOLDS AND APPLICATIONS THEREOF | Non-Final OA | Ecovative LLC |
| 17769663 | BIOLOGICALLY SYNTHESIZED HYDROXYAPATITE FOR BONE REGENERATION AND TISSUE ENGINEERING | Non-Final OA | BIOVENTURES, LLC |
| 18310510 | GENERATING ARTERIAL ENDOTHELIAL CELL POPULATIONS | Non-Final OA | WISCONSIN ALUMNI RESEARCH FOUNDATION |
| 18459381 | CELL CULTURE PROCESS | Non-Final OA | Pfizer Inc. |
| 17560680 | ENHANCED DIFFERENTIATION OF BETA CELLS | Non-Final OA | Vertex Pharmaceuticals Incorporated |
| 18234470 | METHODS FOR CELL EXPANSION, DIFFERENTIATION, AND/OR HARVESTING OF NATURAL KILLER CELLS USING HOLLOW-FIBER MEMBRANES | Non-Final OA | Terumo BCT, Inc. |
| 18038489 | COMPOSITION OF PREDATORY NEMATODES AND METHODS OF USING SAME | Non-Final OA | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization |
| 18264396 | MESENCHYMAL STEM CELLS AND ADIPOCYTES FOR PREPARING MITOKINE MIXTURE, AND THERAPEUTIC OR PROPHYLACTIC DRUG | Non-Final OA | TOKYO UNIVERSITY OF SCIENCE FOUNDATION |
| 18556783 | MESENCHYMAL STEM CELLS HAVING ENHANCED OSTEOGENIC DIFFERENTIATION CAPACITY, AND USE THEREOF | Non-Final OA | SUNGKWANG MEDICAL FOUNDATION |
| 18553904 | METHOD FOR PRODUCING CELL GROWTH MEDIUM | Non-Final OA | Solar Foods Oyj |
| 18551075 | STEM CELLS FOR USE IN REDUCING THE IMMUNE RESPONSE FOLLOWING ORGAN TRANSPLANTATION | Non-Final OA | Amniotics AB |
| 18452726 | SKIN TISSUE | Final Rejection | THE UNIVERSITY OF DURHAM |
| 18363642 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 17771290 | PROTEIN-BASED BIOMATERIAL WITH VISCOELASTIC BEHAVIOUR, PROCESS FOR OBTAINING IT AND USES THEREOF | Non-Final OA | INSERM - Institut National de la Santé et de la Recherche Médicale |
| 18256866 | PHARMACEUTICAL COMPOSITION INCLUDING ADIPOSE-DERIVED REGENERATIVE CELLS (ADRCS) FOR USE IN PREVENTION AND TREATMENT OF LIVER FIBROSIS OR LIVER CIRRHOSIS | Non-Final OA | CYTORI THERAPEUTICS K.K. |
| 18039381 | OPTOGENETIC MODULATION OF ACTION-POTENTIAL PROPERTIES | Non-Final OA | RAMBAN MEDTECH LTD. |
| 15107152 | CONVERGENCE OF AGGREGATION RATE WITH VALIDATED PERIPHERAL DIAGNOSTIC FOR ALZHEIMER'S DISEASE | Final Rejection | West Virginia University |
| 18034645 | ARTIFICIAL AXON BUNDLE | Final Rejection | Jiksak Bioengineering Inc. |
| 18031736 | CONTINUOUS HIGH CELL-DENSITY CULTURE WITH DUAL-VESSEL TANGENTIAL FLOW FILTRATION | Non-Final OA | AGC BIOLOGICS, INC. |
| 18021650 | DEVICE AND A METHOD FOR ORGAN PRESERVATION | Non-Final OA | A.A. Cash Technology Ltd. |
| 17905590 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | Non-Final OA | Universite de Lausanne |
| 18018490 | AQUEOUS SOLUTION TO PRESERVE NUCLEIC ACIDS | Non-Final OA | Biofarma S.r.l. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy